[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652623":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":55,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":25,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants will undergo FAPI-RuiJ PET\u002FCT or PET\u002FMR, followed by FAPI-04 imaging on a separate day","EXPERIMENTAL","Participants will undergo paired PET\u002FCT or PET\u002FMR imaging sequentially, with FAPI-RuiJ administered first and FAPI-04 on a separate day (interval: 1-7 days). For each tracer, a single intravenous injection will be given, followed by whole-body image acquisition at a standardized post-injection time. All images will be independently reviewed by two blinded nuclear medicine physicians. Histopathology or imaging follow-up serves as the reference standard.",[13,14],"Diagnostic Test: FAPI-RuiJ","Diagnostic Test: FAPI-04",{"label":16,"type":10,"description":17,"interventionNames":18},"Participants will undergo FAPI-04 PET\u002FCT or PET\u002FMR, followed by FAPI-RuiJ imaging on a separate day","Participants will undergo paired PET\u002FCT or PET\u002FMR imaging sequentially, with FAPI-04 administered first and FAPI-RuiJ on a separate day (interval: 1-7 days). For each tracer, a single intravenous injection will be given, followed by whole-body image acquisition at a standardized post-injection time. All images will be independently reviewed by two blinded nuclear medicine physicians. Histopathology or imaging follow-up serves as the reference standard.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIAGNOSTIC_TEST","FAPI-RuiJ","A novel FAP-targeted radiotracer for PET\u002FCT or PET\u002FMR imaging; administered intravenously.",[16,9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"FAPI-04","A FAP-targeted radiotracer for PET\u002FCT or PET\u002FMR imaging; administered intravenously.",[16,9],[31],{"name":32,"affiliation":5,"role":33},"Biao Li","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Ying Miao","CONTACT","0086-13671921521","myada821@hotmail.com",[41],{"facility":42,"status":43,"city":44,"state":25,"zip":25,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","RECRUITING","Shanghai","China","CN",{"type":48,"coordinates":49},"Point",[50,51],121.45806,31.22222,{"lat":51,"lon":50},[54],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},{"type":56,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100652623","clinical-applications-of-fapi-pet-in-solid-tumors-100652623",false,"NCT07776899","Clinical Applications of FAPI PET in Solid Tumors","Clinical Applications of Novel FAPI PET in Diverse Solid Tumors","Inclusion Criteria:\n\n1. Age ≥ 18 years and ≤ 80 years, regardless of gender.\n2. Participants with suspected, confirmed, or suspected recurrent solid tumors.\n3. Participants who agree to participate in this clinical trial and provide written informed consent.\n4. Participants with good compliance, who commit to adhering to the study procedures and cooperate with the full study process.\n5. No plans for pregnancy within 6 months.\n\nExclusion Criteria:\n\n1. Patients with severe medical conditions that, in the investigator's opinion, make them unsuitable for participation in this clinical study, including but not limited to: severe cardiopulmonary insufficiency, severe bone marrow suppression, and severe hepatic or renal insufficiency.\n2. Patients with claustrophobia, severe psychiatric symptoms, or impaired consciousness that precludes cooperation with the examination procedures.\n3. Patients who have received any anti-tumor therapy during the interval between the two PET imaging sessions.\n4. Pregnant or breastfeeding women.\n5. Patients with poor compliance.","ALL","18 Years","80 Years",{"count":68,"type":69},200,"ESTIMATED","INTERVENTIONAL",[72],"NA","The study systematically evaluates the diagnostic performance of FAPI-RuiJ and FAPI-04 PET\u002FCT or PET\u002FMR in various solid tumor types, and is expected to provide a novel molecular imaging tool for early lesion detection, accurate staging, and recurrence surveillance in patients with solid tumors.",[75],"Solid Tumor","2026-08-17",{"date":78,"type":79},"2026-08-20","ACTUAL",{"date":81,"type":79},"2026-07-02",{"date":83,"type":69},"2029-03-31",{"name":5,"class":6},1]